Xolair 150mg

Ways of use

Omalizumab is intended to monitor and avert symptoms (like wheezing or panting) caused by asthma. Monitoring the signs of asthma allows you deal with your daily activities and reduces the duration of disease. The drug is also aimed at treating hives caused by an unknown reason (CIU). To achieve the best effect, you should use Omalizumab on a regular basis. Its action is manifested not at once. In case of asthma attack, use your quick-relief inhaler (like salbutamol or albuterol) as necessary.

Indications for use

Asthma

Xolair 150 mg can be used by patients over the age of 6 and old people, suffering from moderate to severe asthma with a positive skin test or to a perennial aeroallergen and whose signs are inadequately monitored with inhaled corticosteroids.

Xolair is able to reduce the incidence of asthma exacerbations in such patients.

Restrictions

Xolair is not intended for the treatment of bronchospasm, acute severe asthma or other allergies.

Chronic Idiopathic Urticaria (CIU)
Xolair 150 mg is used for the therapy of adults, teens over the age of 12 years and old patients with CIU after the failure of H1 antihistamine treatment.

Restrictions on use

Xolair must not be used for the treatment of other forms of urticaria.

Way of use and dosage
Asthma

Take 75-375 mg Xolair subcutaneously every two-four weeks. Define the dosage (mg) and frequency of use by measuring Immunoglobulin E (IU/mL) and your weight (kg).

In case of significant weight gain/loss, the dose should be adjusted.
Xolair is administered by means of subcutaneous injection. This process may take about ten seconds, as the solution is a bit viscous. Don’t exceed the single dose of 150 mg (contents of one vial) per injection area. If necessary, divide higher doses among several injection areas.

Adverse effects

Most drugs cause adverse effects. Adverse effect is an undesirable reaction to a drug when it is taken in common doses. They can be minor or severe, transient or long-lasting.

The following adverse effects listed are not experienced by every patient using this drug. If you are worried about adverse effects, discuss the risks and advantages of this drug with your physician.

Consult your physician if you experience these adverse effects and they become serious or annoying. Your doctor may tell you how to deal with adverse effects.

With the use of Xolair 150 mg during the first 16 weeks in clinical trials, there was a decrease in the incidence of exacerbations of bronchial asthma, a reduction in the number of cases of emergency therapy, and improvement in the symptoms of the disease. Evaluation of the effectiveness of therapy with Xolair 150 mg should be carried out at least 12 weeks after treatment with the drug.

The drug Xolair 150 mg is intended for long-term therapy. The withdrawal of the drug usually leads to a return of elevated levels of free IgE and the development of the corresponding symptoms.
The overall level of IgE increases during treatment and remains elevated for 1 year after cessation of therapy. Thus, the level of IgE when re-determined against the background of therapy with Xolair 150 mg can not serve as a guide for the selection of the dose of the drug.